Login and fund life
HairClone is a startup biotechnology company focused on developing personalised treatments using a patient’s own cultured hair cells to reverse hair loss. Step one of this process which involves looking to create what aims to be the world's first follicle banking service, to be launched in 2019.
Prototyping, preclinical
Hair loss (androgenic alopecia)
£3,000,000
9.09%
HairClone is aiming to enter a very large market worth $4bn for surgical hair restoration alonesource. With their rejuvenation arm of the business, they hope to grow this market by attracting a whole new set of customers.
Furthermore, early biobanking of hair cells increases the likelihood of future hair rejuvenation/regeneration and could, therefore, build continuous revenues for the business.
HairClone’s 2nd therapy is still in a testing phase and currently, there are no supporting figures for the success rate of the treatments. Other risks associated with an investment of this type can be found here.
What our experts say
The final rating*
£3,000,000
9.09%
£100
Sign up for more information
Register now to download the data sheet of this opportunity.
It´s free, easy and fast
HairClone is developing two personalised therapies to treat the most common cause of hair loss in men and women (androgenic alopecia). HairClone's lead treatment aims to rejuvenate thinning hairs for patients when they first notice hair loss, their second treatment aims to regenerate brand new hair follicles for patients with extensive hair loss. These treatments, if successful, would dramatically
revolutionise the market by filling the unmet needs of women with female pattern baldness, men for whom it is too early in the balding process for hair transplantation to be recommended and patients who need greater coverage than can be achieved by transplantation. In 2019 HairClone aims to launch the world's first hair follicle banking service which will allow patients to store a small number of hair follicles for future expansion. They have an expanding clinical partner network of leading hair transplant surgeons around the world who are providing non-dilutive co-funding and a deep clinical know-how and expertise, linking them to patients for both banking and later treatment.
The team
Executive Team
Paul is a founding Director of HairClone. He has over 25 years’ experience in the development and commercialisation of Regenerative Medicine and Cell Therapy products. He has developed commercialised cell therapy treatments and grown companies from founding to flotation. He has raised over £25M from International VC funds and previously he has held Executive Board level positions in both public and private Companies in the UK and US (Organogenesis, Intercytex).
Vincent has more than 28 years of experience of applied research and product development in the fields of regenerative medicine, wound healing and cosmetics. He has worked in companies in Europe, United States and Asia (Organogenesis, L’Oreal, Smith and Nephew). He is currently Scientific Director of HairClone (UK) and Chief Innovation Officer at Cutiss AG (Switzerland).
Qualified from the Royal College of Surgeons in Ireland and co-founded the Farjo Hair Institute in 1993 exclusively offering hair transplant surgery and hair restoration medicine. Dr Farjo is a Past President of both British Association of Hair Restoration Surgery and International Society of Hair Restoration Surgery. He is a diplomate of American Board of Hair Restoration Surgery, Past Medical Director of Institute of Trichologists and member of European Hair Research Society.
Nilofer Farjo has been performing hair transplants for 25 years and is recognised for her educational and leadership contributions at international congresses and meetings. She also has been acknowledged by her peers for outstanding achievement in basic science or clinically-related research in hair pathophysiology or anatomy as it relates to hair restoration for which she was awarded the ISHRS Platinum Award in 2012. Nilofer currently works on hair biology research with six UK Universities.
Eric is a serial entrepreneur who has raised nearly €90 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-founder of four biotechnology companies called Myosix, Murigenetics, HairClone and Digital Orthopaedics. Eric is also Board member of the biotechnology companies Bioxodes, VitriCell and Innobiochips. He was principal of the life sciences practice of Arthur D. Little in Paris and Boston.
Join now to see the rest of HairClone’s pitch.
Register with your email
Do you have and account?, please Login here
Insert a widget in your web page
Share this project in your website. Copy and paste the following code in your content
Copied!
Preview